Is FEMY or SLNO more profitable?

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Soleno Therapeutics 33.70% 22.85% 18.25%

Do analysts prefer STVN or SLNO?

Soleno Therapeutics has a consensus price target of $76.67, indicating a potential upside of 44.63%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Soleno Therapeutics 2 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.08

This company has been marked as potentially delisted and may not be actively trading.

Soleno Therapeutics (SLNO) Competitors

Compare

SLNO vs. FEMY, IMVT, GKOS, STVN, and BLCO

Should you buy Soleno Therapeutics stock or one of its competitors? MarketBeat compares Soleno Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Glaukos (GKOS), Stevanato Group (STVN), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector.

How does Soleno Therapeutics compare to Femasys?

Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Soleno Therapeutics	33.70%	22.85%	18.25%

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	8.08	-$18.63M	-$0.27	N/A
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

Femasys has a beta of -2.23, meaning that its share price is 323% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, meaning that its share price is 322% less volatile than the broader market.

In the previous week, Femasys had 3 more articles in the media than Soleno Therapeutics. MarketBeat recorded 3 mentions for Femasys and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 beat Femasys' score of -0.03 indicating that Soleno Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
Soleno Therapeutics	Positive

65.3% of Femasys shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 7.6% of Femasys shares are owned by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Femasys currently has a consensus target price of $5.33, suggesting a potential upside of 1,640.64%. Soleno Therapeutics has a consensus target price of $76.67, suggesting a potential upside of 44.63%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Soleno Therapeutics beats Femasys on 11 of the 15 factors compared between the two stocks.

How does Soleno Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Immunovant currently has a consensus price target of $37.33, indicating a potential upside of 20.00%. Soleno Therapeutics has a consensus price target of $76.67, indicating a potential upside of 44.63%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Soleno Therapeutics has a net margin of 33.70% compared to Immunovant's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Soleno Therapeutics	33.70%	22.85%	18.25%

Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

In the previous week, Immunovant had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 2 mentions for Immunovant and 0 mentions for Soleno Therapeutics. Immunovant's average media sentiment score of 1.19 beat Soleno Therapeutics' score of 0.94 indicating that Immunovant is being referred to more favorably in the media.

Company	Overall Sentiment
Immunovant	Positive
Soleno Therapeutics	Positive

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, meaning that its stock price is 322% less volatile than the broader market.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Soleno Therapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Soleno Therapeutics compare to Glaukos?

Glaukos (NYSE:GKOS) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Soleno Therapeutics has a net margin of 33.70% compared to Glaukos' net margin of -34.34%. Soleno Therapeutics' return on equity of 22.85% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Soleno Therapeutics	33.70%	22.85%	18.25%

Soleno Therapeutics has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	14.44	-$187.69M	-$3.28	N/A
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

In the previous week, Glaukos had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 2 mentions for Glaukos and 0 mentions for Soleno Therapeutics. Glaukos' average media sentiment score of 1.23 beat Soleno Therapeutics' score of 0.94 indicating that Glaukos is being referred to more favorably in the media.

Company	Overall Sentiment
Glaukos	Positive
Soleno Therapeutics	Positive

Glaukos has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, suggesting that its stock price is 322% less volatile than the broader market.

Glaukos presently has a consensus target price of $146.17, indicating a potential upside of 17.13%. Soleno Therapeutics has a consensus target price of $76.67, indicating a potential upside of 44.63%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

99.0% of Glaukos shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Glaukos and Soleno Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Soleno Therapeutics compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Soleno Therapeutics has a consensus price target of $76.67, indicating a potential upside of 44.63%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Stevanato Group has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.19	€158.21M	€0.59	31.49
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

In the previous week, Stevanato Group had 5 more articles in the media than Soleno Therapeutics. MarketBeat recorded 5 mentions for Stevanato Group and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 beat Stevanato Group's score of 0.67 indicating that Soleno Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Stevanato Group	Positive
Soleno Therapeutics	Positive

97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Stevanato Group has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, indicating that its stock price is 322% less volatile than the broader market.

Soleno Therapeutics has a net margin of 33.70% compared to Stevanato Group's net margin of 11.76%. Soleno Therapeutics' return on equity of 22.85% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Soleno Therapeutics	33.70%	22.85%	18.25%

Summary

Soleno Therapeutics beats Stevanato Group on 9 of the 16 factors compared between the two stocks.

How does Soleno Therapeutics compare to Bausch + Lomb?

Soleno Therapeutics (NASDAQ:SLNO) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Soleno Therapeutics has a beta of -2.22, indicating that its stock price is 322% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

In the previous week, Bausch + Lomb had 5 more articles in the media than Soleno Therapeutics. MarketBeat recorded 5 mentions for Bausch + Lomb and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 beat Bausch + Lomb's score of 0.72 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Bausch + Lomb	Positive

Soleno Therapeutics currently has a consensus price target of $76.67, indicating a potential upside of 44.63%. Bausch + Lomb has a consensus price target of $17.92, indicating a potential upside of 15.73%. Given Soleno Therapeutics' higher probable upside, equities research analysts clearly believe Soleno Therapeutics is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Soleno Therapeutics has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Bausch + Lomb	$5.10B	1.08	-$360M	-$0.62	N/A

Soleno Therapeutics has a net margin of 33.70% compared to Bausch + Lomb's net margin of -4.21%. Soleno Therapeutics' return on equity of 22.85% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Bausch + Lomb	-4.21%	3.60%	1.69%

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Soleno Therapeutics beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

Get Soleno Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLNO vs. The Competition

Export

Metric	Soleno Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.76B	$2.96B	$6.66B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.56%
P/E Ratio	29.95	18.12	24.03	23.62
Price / Sales	9.69	286.06	513.89	111.51
Price / Cash	124.10	56.17	26.99	37.22
Price / Book	5.57	3.83	10.24	6.66
Net Income	$20.89M	$75.85M	$3.57B	$337.55M

Soleno Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLNO Soleno Therapeutics	3.8055 of 5 stars	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
FEMY Femasys	2.0047 of 5 stars	$0.38 -2.4%	$5.33 +1,311.3%	-61.7%	$23.37M	$2.29M	N/A	30	News Coverage Analyst Upgrade Stock Split Gap Down
IMVT Immunovant	2.6349 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+85.5%	$6.75B	N/A	N/A	120	Gap Up
GKOS Glaukos	2.7772 of 5 stars	$103.41 +0.1%	$146.17 +41.3%	+34.1%	$6.07B	$507.44M	N/A	1,094	Positive News
STVN Stevanato Group	2.345 of 5 stars	€18.86 -0.1%	N/A	-21.9%	€5.71B	€1.34B	31.97	6,010	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLNO) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soleno Therapeutics (SLNO) Competitors

SLNO vs. FEMY, IMVT, GKOS, STVN, and BLCO

How does Soleno Therapeutics compare to Femasys?

Summary

How does Soleno Therapeutics compare to Immunovant?

Summary

How does Soleno Therapeutics compare to Glaukos?

Summary

How does Soleno Therapeutics compare to Stevanato Group?

Summary

How does Soleno Therapeutics compare to Bausch + Lomb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO vs. The Competition

Soleno Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soleno Therapeutics (SLNO) Competitors

SLNO vs. FEMY, IMVT, GKOS, STVN, and BLCO

How does Soleno Therapeutics compare to Femasys?

Is FEMY or SLNO more profitable?

Which has better earnings and valuation, FEMY or SLNO?

Which has more volatility & risk, FEMY or SLNO?

Does the media prefer FEMY or SLNO?

Do institutionals and insiders have more ownership in FEMY or SLNO?

Do analysts rate FEMY or SLNO?

Summary

How does Soleno Therapeutics compare to Immunovant?

Do analysts rate IMVT or SLNO?

Is IMVT or SLNO more profitable?

Which has stronger valuation and earnings, IMVT or SLNO?

Does the media favor IMVT or SLNO?

Which has more risk & volatility, IMVT or SLNO?

Do institutionals and insiders believe in IMVT or SLNO?

Summary

How does Soleno Therapeutics compare to Glaukos?

Is GKOS or SLNO more profitable?

Which has stronger earnings and valuation, GKOS or SLNO?

Does the media refer more to GKOS or SLNO?

Which has more volatility and risk, GKOS or SLNO?

Do analysts recommend GKOS or SLNO?

Do insiders & institutionals have more ownership in GKOS or SLNO?

Summary

How does Soleno Therapeutics compare to Stevanato Group?

Do analysts prefer STVN or SLNO?

Which has higher valuation & earnings, STVN or SLNO?

Does the media prefer STVN or SLNO?

Do institutionals and insiders have more ownership in STVN or SLNO?

Which has more risk and volatility, STVN or SLNO?

Is STVN or SLNO more profitable?

Summary

How does Soleno Therapeutics compare to Bausch + Lomb?

Which has more risk and volatility, SLNO or BLCO?

Does the media favor SLNO or BLCO?

Do analysts recommend SLNO or BLCO?

Which has better valuation and earnings, SLNO or BLCO?

Is SLNO or BLCO more profitable?

Do insiders & institutionals believe in SLNO or BLCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO vs. The Competition

Soleno Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools